The evidence for disease modification in Parkinson's disease

International Journal of Neuroscience

Volumn 121, Issue SUPPL. 2, 2011, Pages 18-26

  Lew, Mark F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Clinical trials; Neuroprotection; Parkinson's disease (PD)

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; PLACEBO; PRAMIPEXOLE; RASAGILINE; SELEGILINE; TOCOPHEROL; UBIDECARENONE;

ARTICLE; CHRONICITY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; EARLY INTERVENTION; EXERCISE; HUMAN; KINESIOTHERAPY; NEUROPROTECTION; PARKINSON DISEASE; PHARMACEUTICAL CARE;

ANTIPARKINSON AGENTS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 80155177695     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.620194     Document Type: Article

References (40)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neeley and Jones; 1817.
2. Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinsons disease. Drugs Aging. 1991;1:228-48.
3. YoudimMB, Bar AO, Yogev-Falach Weinreb O,MaruyamaW, Naoi M, Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79:172-9. (Pubitemid 40116432)
4. Zou L, Jankovic J, Rowe DB,XieW, Appel S, LeW. Neuroprotection of pramipexole against dopamine and levodopa-induced cytotoxicity. Life Sci. 1999;64:1275-85. (Pubitemid 29156855)
5. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic neurons in aged mice. Brain Res. 1998;783:109-114. (Pubitemid 28131427)
6. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinsons disease. N Engl J Med. 1989 Nov 16;321(20):1364-71.
7. The Parkinsons Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinsons disease. N Engl J Med. 1993:328;176-83.
8. The Parkinsons Study Group. Impact of deprenyl and tocopherol treatment on Parkinsons disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39:29-36.
9. The Parkinsons Study Group. Impact of deprenyl and tocopherol treatment on Parkinsons disease in DATATOP subjects requiring levodopa. Ann Neurol. 1996:39:37-45.
10. Palhagen S, Heinonen E, Hägglund J, Kaugesaar T,Mäki-Ikola O, Palm R; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms Parkinsons disease. Neurology. 2006;66:1200-06. (Pubitemid 43739704)
11. Leber P. Slowing the progression of Alzheimers disease: methodological issues. AlzheimerDis AssocDis. 1997;11 Suppl 5:S10-21. (Pubitemid 27472532)
12. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinsons disease. Science. 1989;245:519-22. (Pubitemid 19204003)
13. Rascol O. Disease modification trials in Parkinsons disease: target populations, endpoints and study design. Neurology. 2009:72:S51-8.
14. The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Arch Neurol. 2002;59:1937-43.
15. The Parkinson Study Group. A controlled, randomized, delayed start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-6.
16. Hauser RA, LewMF, Hurtig HI, Ondo W,Wojcieszek J, Fitzer-Attas CJ, on behalf of the TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinsons disease. Mov Disord. 2009;24:564-73.
17. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, for the ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinsons disease. N Engl J Med. 2009;361:1268-78.
18. Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K. Rationale for delayed-start study of pramipexole in Parkinsons disease: the PROUD study. Mov Disord. 2010 Aug 15;25(11):1627-32.
19. Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O,Marek K, on behalf of the PROUDStudy Group. Immediate vs. delayed start pramipexole in early Parkinsons disease: the PROUD Study (poster 1.278). Poster session presented at: WFN XVIII World Congress on Parkinsons Disease and Related Disorders; 2009 Dec 1316; Miami, FL.
20. The Parkinson Study Group. Levodopa and the progression of Parkinsons disease. N Engl J Med. 2004;351:2498-508.
21. Fahn S; The Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinsons disease? J Neurol. 2005;252 Suppl 4: IV/37-42.
22. Parker WJ Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinsons disease. Ann Neurol. 1989;26:719-23. (Pubitemid 20011004)
23. Kridge D, Carroll MT, Cooper JM, Marsden CD, Schapira AHV. Platelet mitochondrial function in Parkinsons disease. Ann Neurol. 1992;32:782-8.
24. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with activities of complexes I and II/III in mitochondria from parkinsonian and non-parkinsonian subjects. Ann Neurol. 1997;42:261-4. (Pubitemid 27340475)
25. Schults C, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; The Parkinson Study Group. Effects of Coenzyme Q10 in early Parkinsons disease: evidence of slowing the functional decline. Arch Neurol. 2002;59:1541-50.
26. Beale C, Shoulson I, Oakes D; NINDS. Effects of Coenzyme Q10 in Parkinson disease Internet.. Bethesda (MD): National Institutes of Health (NIH). 2008 -2011 Sept 22.. Available from: http://clinicaltrials.gov/ct2/show/NCT00740714.
27. Beale C, Shoulson I, Oakes D; NINDS. Effects of Coenzyme Q10 in Parkinson disease. Statement on the termination of the QE3 Study Internet.. Bethesda (MD): National Institutes of Health (NIH) Neurological Institute.2011 May 27 updated 2011 Jun 2; 2011 Sept 22.. Available from: http://www.ninds.nih.gov/ disorders/clinicaltrials/CoQ10-Trial-Update.htm.
28. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006 Mar 14;66(5):664-71.
29. NINDS NET-PD Investigators. A randomized clinical trial of Coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 Jan 2;68(1):20-28.
30. NINDS NET-PD Investigators. NET-PD LS-1 creatine in Parkinsons disease Internet.. Bethesda (MD): National Institutes of Health (NIH) Neurological Institute. 2011 Sept 22.. Available from: http://www.ninds.nih.gov/disorders/ clinical trials/NCT00449865.htm.
31. Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul C, Jakowec MW. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res. 2004;77:378-90. (Pubitemid 38970982)
32. Fisher BE,Wu AD, Salem GJ, Song J, Lin J, Yip J, Cen S, Gordon J, Jakowec M, Petzinger G. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinsons disease. Arch Phys Med Rehabil. 2008 Jul;89(7):1221-29. (Pubitemid 351884995)
33. Petzinger GM, Fisher BE, Van Leeuwen JE, Vukovic M, Akopian G, Meshul CK, Holschneider DP, Nacca A, Walsh J, Jakowec MJ. Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinsons disease. Mov Disord. 2010;25 Suppl 1:S141-5.
34. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ. Rejuvenation protects neurons in mouse models of Parkinsons disease. Nature. 2007;447:1081-6. (Pubitemid 47014425)
35. Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinsons disease. Mov Disord. 2010;25 Suppl 1:S63-70.
36. The Parkinson Study Group; Michael J; Fox Foundation for Parkinsons Research and Northwestern University; Simuni T. Safety, tolerability and efficacy assessment of Dynacirc CR in Parkinsons disease (STEADYPD) Internet.. Bethesda (MD): National Institutes of Health (NIH).2009-2011 Sept 22.. Available from: http://clinicaltrials.gov/ct2/show?term=isradipine&rank=2.
37. Schwarzschild M, Michael J; Fox Foundation for Parkinsons Research. Safety of urate elevation in Parkinsons disease (SURE-PD) Internet.. Bethesda (MD): National Institutes of Health (NIH).2009 -2011 Sept 22.. Available from: http://www.pdtrials.org/en/browse/all/view/259.
38. Yeum KJ, Russell RM, Krinsky NI, Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys. 2004;430:97-103. (Pubitemid 39119784)
39. Luo W, Schwarzschild MA, Xu K. Urate attenuates MPTPinduced dopaminergic neurotoxicity in mice [abstract no.797.8]. Paper presented at: Annual Meeting of the Society for Neuroscience; 2007 Nov 3-7; San Diego, CA.
40. Weisskopf MG, OReilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinsons disease. Am J Epidemiol. 2007;166:561-7. (Pubitemid 47283643)